The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Open accessAbstract
Regulatory T (T reg) cells are the major obstacle to cancer immunotherapy, and their depletion promptly induces conversion of peripheral precursors into T reg cells. We show that T reg cells can be functionally inactivated by OX40 triggering. In tumors, the vast majority of CD4+ T cells are Foxp3+ and OX40bright. However, intratumor injection of the agonist anti-OX40 monoclonal antibody (mAb) OX86, but not anti-CD25 mAb, induces tumor rejection in 80% of mice, an effect that is abrogated by CD8 depletion. Upon intratumor OX40 triggering, increased numbers of infiltrating dendritic cells (DCs) migrate to draining lymph nodes and generate a new wave of tumor-specific cytotoxic T lymphocytes, as detected by tetramer and CD44 staining of node CD8+ T lymphocytes. Tumor-bearing Rag1-knockout (KO) mice reconstituted with OX40-deficient T reg cells and wild-type (WT) effector T cells, or the reciprocal combination, showed that both T reg and effector T cells must be triggered via OX40 for the tumor to be rejected. Accordingly, WT but not OX40-KO mice receiving intratumor coinjection of OX86 and ovalbumin protein were able to revert tumor-induced tolerization of adoptively transferred OX40-competent OTII T lymphocytes. In conclusion, OX40-mediated inactivation of T reg cell function unleashes nearby DCs, allowing them to induce an adaptive immune response. In addition, the known OX40-dependent delivery of fitness signals to activated T cells is boosted by concurrent T reg cell inhibition. OX40 triggering thus has multiple effects that converge to mediate tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Förster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Müller, I., Wolf, E., & Lipp, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80059-8 · Cited by 2,367
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,568
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
Tang, Q., Adams, J. Y., Tooley, A. J., Bi, M., Fife, B. T., Serra, P., Santamaria, P., Locksley, R. M., Krummel, M. F., & Bluestone, J. A. (2006) · Nature Immunology · doi:10.1038/ni1289 · Cited by 774
OX40 Promotes Bcl-xL and Bcl-2 Expression and Is Essential for Long-Term Survival of CD4 T Cells
Rogers, P. R., Song, J., Gramaglia, I., Killeen, N., & Croft, M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00191-1 · Cited by 646
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo
Tadokoro, C. E., Shakhar, G., Shen, S., Ding, Y., Lino, A. C., Maraver, A., Lafaille, J. J., & Dustin, M. L. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050783 · Cited by 527
Bromley, S. K., Thomas, S. Y., & Luster, A. D. (2005) · Nature Immunology · doi:10.1038/ni1240 · Cited by 509
Activated CD4+CD25+ T cells selectively kill B lymphocytes
Zhao, D.-M., Thornton, A. M., DiPaolo, R. J., & Shevach, E. M. (2006) · Blood · doi:10.1182/blood-2005-11-4502 · Cited by 506
Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues
Debes, G. F., Arnold, C. N., Young, A. J., Krautwald, S., Lipp, M., Hay, J. B., & Butcher, E. C. (2005) · Nature Immunology · doi:10.1038/ni1238 · Cited by 474
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462
Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 432
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
Self-citationOX40 costimulation turns off Foxp3+ Tregs
Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N., Ishii, N., & Chang Li, X. (2007) · Blood · doi:10.1182/blood-2007-01-070748 · Cited by 428
Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N., & Croft, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3043 · Cited by 409
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Self-citationEngagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Self-citationTherapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
Kohm, A. P., McMahon, J. S., Podojil, J. R., Begolka, W. S., DeGutes, M., Kasprowicz, D. J., Ziegler, S. F., & Miller, S. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3301 · Cited by 332
CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells
Schneider, M. A., Meingassner, J. G., Lipp, M., Moore, H. D., & Rot, A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061405 · Cited by 321
Möttönen, M., Heikkinen, J., Mustonen, L., Isomäki, P., Luukkainen, R., & Lassila, O. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02754.x · Cited by 320
Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells
Takeda, I., Ine, S., Killeen, N., Ndhlovu, L. C., Murata, K., Satomi, S., Sugamura, K., & Ishii, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3580 · Cited by 308
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
The GITR–GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Shevach, E. M., & Stephens, G. L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1867 · Cited by 281
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Zhou, G., Drake, C. G., & Levitsky, H. I. (2006) · Blood · doi:10.1182/blood-2005-07-2737 · Cited by 272
Valzasina, B., Piconese, S., Guiducci, C., & Colombo, M. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4217 · Cited by 259
Self-citationThe tumor‐draining lymph node as an immune‐privileged site
Munn, D. H., & Mellor, A. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00444.x · Cited by 251
Signaling through OX40 (CD134) breaks peripheral T-cell tolerance
Bansal-Pakala, P., Gebre-Hiwot Jember, A., & Croft, M. (2001) · Nature Medicine · doi:10.1038/90942 · Cited by 230
Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S., & Katsanis, E. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0160-8 · Cited by 225
Zhou, G., & Levitsky, H. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2155 · Cited by 213
So, T., & Croft, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1427 · Cited by 210
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 208
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
Cohen, A. D., Diab, A., Perales, M.-A., Wolchok, J. D., Rizzuto, G., Merghoub, T., Huggins, D., Liu, C., Turk, M. J., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2813 · Cited by 202
Kjærgaard, J., Tanaka, J., Kim, J. A., Rothchild, K. B., Weinberg, A. D., & Shu, S. (2000) · PubMed · Cited by 197
Costimulation of CD8 T Cell Responses by OX40
Bansal-Pakala, P., Halteman, B. S., Cheng, M. H.-Y., & Croft, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4821 · Cited by 175
Ramirez-Montagut, T., Chow, A., Hirschhorn-Cymerman, D., Terwey, T. H., Kochman, A. A., Lu, S., Miles, R. C., Sakaguchi, S., Houghton, A. N., & van den Brink, M. R. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6434 · Cited by 173
Modulation of Dendritic Cell Function by Naive and Regulatory CD4+ T Cells1
Veldhoen, M., Moncrieffe, H., Hocking, R. J., Atkins, C., & Stockinger, B. (2006) · Journal of Immunology · doi:10.4049/jimmunol.176.10.6202 · Cited by 152
Stephens, L. A., Gray, D., & Anderton, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507454102 · Cited by 122
Pan, P., Zang, Y., Weber, K. J., Meseck, M. L., & Chen, S. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0699 · Cited by 122
OX40-OX40 Ligand Interaction through T Cell-T Cell Contact Contributes to CD4 T Cell Longevity
Soroosh, P., Ine, S., Sugamura, K., & Ishii, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5975 · Cited by 106
Murata, S., Ladle, B. H., Kim, P. S., Lutz, E. R., Wolpoe, M. E., Ivie, S. E., Smith, H. M., Armstrong, T. D., Emens, L. A., Jaffee, E. M., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.974 · Cited by 106
Hiura, T., Kagamu, H., Miura, S., Ishida, A., Tanaka, H., Tanaka, J., Gejyo, F., & Yoshizawa, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5058 · Cited by 101
Lathrop, S. K., Huddleston, C. A., Dullforce, P. A., Montfort, M. J., Weinberg, A. D., & Parker, D. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6735 · Cited by 90
Dercamp, C., Chemin, K., Caux, C., Trinchieri, G., & Vicari, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1319 · Cited by 70
Gri, G., Gallo, E. M., Carlo, E. D., Musiani, P., & Colombo, M. P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.99 · Cited by 65
Self-citationZelenay, S., & Demengeot, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2036-a · Cited by 59
OX40 (CD134) engagement drives differentiationof CD4+ T cells to effector cells
Huddleston, C. A., Weinberg, A. D., & Parker, D. C. (2006) · European Journal of Immunology · doi:10.1002/eji.200535637 · Cited by 57
Cooperation between CD4 and CD8 T cells for anti‐tumor activity is enhanced by OX40 signals
Song, A., Song, J. J., Tang, X., & Croft, M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636957 · Cited by 52
Activated T cells express the OX40 ligand: requirements for induction and costimulatory function
Mendel, I., & Shevach, E. M. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02279.x · Cited by 48
Imaging the function of regulatory T cells in vivo
Tang, Q., & Krummel, M. F. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.05.007 · Cited by 45
Nocentini, G., Bartoli, A., Ronchetti, S., Giunchi, L., Cupelli, A., Delfino, D. V., Migliorati, G., & Riccardi, C. (2000) · DNA and Cell Biology · doi:10.1089/104454900314474 · Cited by 33
Almeida, A. R. M., Zaragoza, B., & Freitas, A. A. (2006) · International Immunology · doi:10.1093/intimm/dxl093 · Cited by 18
Cited by
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Metadata
- Authors
- Piconese, S., Valzasina, B., & Colombo, M. P.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-03-24
- Volume
- 205
- Issue
- 4
- Pages
- 825-839
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2106605927
- Cited by
- 405
- References
- 61
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.